BioDelivery Sciences International (BDSI) Posts Earnings Results, Beats Estimates By $0.04 EPS

BioDelivery Sciences International (NASDAQ:BDSI) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.04, Morningstar.com reports. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 278.79%. The company had revenue of $14.16 million for the quarter, compared to analyst estimates of $14.21 million.

BDSI stock traded up $0.09 during mid-day trading on Friday, hitting $3.78. The company had a trading volume of 688,322 shares, compared to its average volume of 731,159. The firm has a market cap of $224.54 million, a price-to-earnings ratio of -9.69 and a beta of 0.09. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.90 and a current ratio of 3.16. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $4.14.

In other BioDelivery Sciences International news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $3.84, for a total value of $30,720.00. Following the sale, the director now owns 522,187 shares of the company’s stock, valued at $2,005,198.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 151,039 shares of BioDelivery Sciences International stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the sale, the director now directly owns 520,482 shares in the company, valued at approximately $1,478,168.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 175,039 shares of company stock worth $503,991. Insiders own 13.26% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. increased its stake in shares of BioDelivery Sciences International by 2.7% in the second quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock worth $3,512,000 after purchasing an additional 30,991 shares in the last quarter. Northern Trust Corp increased its stake in shares of BioDelivery Sciences International by 19.9% in the second quarter. Northern Trust Corp now owns 191,016 shares of the specialty pharmaceutical company’s stock worth $563,000 after purchasing an additional 31,749 shares in the last quarter. Bank of Montreal Can purchased a new position in shares of BioDelivery Sciences International in the second quarter worth about $138,000. PNC Financial Services Group Inc. purchased a new position in shares of BioDelivery Sciences International in the second quarter worth about $148,000. Finally, Wells Fargo & Company MN increased its stake in shares of BioDelivery Sciences International by 121.7% in the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock worth $331,000 after purchasing an additional 64,803 shares in the last quarter. 46.10% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on BDSI. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, October 8th. Cantor Fitzgerald reissued a “buy” rating and set a $4.50 price target on shares of BioDelivery Sciences International in a research report on Thursday, August 9th. Zacks Investment Research raised shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Monday, July 23rd. Finally, Janney Montgomery Scott raised their price target on shares of BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a research report on Friday, November 2nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $4.54.

TRADEMARK VIOLATION NOTICE: “BioDelivery Sciences International (BDSI) Posts Earnings Results, Beats Estimates By $0.04 EPS” was originally reported by WKRB News and is the property of of WKRB News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.wkrb13.com/2018/11/10/biodelivery-sciences-international-bdsi-posts-earnings-results-beats-estimates-by-0-04-eps.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: What is Cost of Debt?

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply